Quarterly Results
ACB Earnings Forecast
Looking ahead, ACB remains a focal point for investors seeking growth opportunities. Analyst forecasts for 2026/Q3 project quarter revenue of 92.43M and an EPS of -0.10.
However, recent estimate revisions provide additional context. Over the past three months, revenue estimates for FY2026 have been No Change by 0%, while EPS estimates have been Revise Upward by 10.08%. For the upcoming Q3 2026, revenue estimates have been adjusted Revise Upward by 0.33% . These revisions correlate with a -30.00% change in stock price over the same period, suggesting potential buying opportunities for investors who believe in ACB long-term fundamentals.
The relationship between earnings forecast revisions and stock price movements is critical for investors. Positive revisions in revenue or EPS often signal strengthening fundamentals, making temporary price dips attractive entry points. Conversely, downward revisions may reflect short-term challenges.
1Y
3Y
5Y
Currency: USD
--
Revenue Estimate-:0
--
EPS Estimate-:0
—
Stock Price0
Earnings Forecast
Revenue
EPS
Currency: CAD
Actual
Estimate
Al Analysis
Earnings Surprise Analysis
Revenue
EPS
1Y
3Y
Al Analysis
Earnings Reaction
The chart below shows how ACB performed 10 days before and after its earnings report, based on data from the past quarters. Typically, ACB sees a +1.38% change in stock price 10 days leading up to the earnings, and a -3.74% change 10 days following the report. On the earnings day itself, the stock moves by +0.80%. This data can give you a slight idea of what to expect for the next quarter's release.
For example, in SEP/2025, the stock changed -2.24% on the day following the earnings release and then changed by -3.59% over the next 10 days. These patterns provide investors with valuable insights into potential price movements and help inform trading strategies around earnings events.
People Also Watch
Frequently Asked Questions
What were the key highlights of ACB's latest earnings report for FY2026Q2?
ACB reported its FY2026Q2 earnings on 2025-11-05, showcasing a revenue of 90.37M against an estimate of 86.45M, resulting in a 4.53% surprise. The EPS was 0.09, surpassing the expected 0.02 by 350% . The stock experienced a -1.76% price change on the earnings day and a 2.86% change over the next five days, reflecting market reactions to the results.
How did ACB's stock price react after the FY2026Q2 earnings release?
Following ACB's FY2026Q2 earnings announcement on 2025-11-05, the stock price moved by -1.76% on the day of the release. Over the subsequent five days, it saw a 2.86% change. Historically, ACB's stock price tends to shift by an average of +1.38% in the 10 days leading up to earnings and -3.74% in the 10 days following, providing insight into potential market.
What are the revenue and EPS estimates for ACB for 2026/Q3?
For 2026/Q3, analysts estimate ACB’s annual revenue to reach 92.43M, while the EPS is projected at -0.10. These estimates reflect recent revisions, with revenue estimates revised Revenue No Change by 0% and EPS estimates Revise Upward by 0.33% over the past three months, indicating analyst expectation in the company’s performance.
How does ACB's stock price correlate with earnings forecast revisions?
The correlation between ACB's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock’s fundamentals. Over the past three months, revenue estimates for FY2026 were No Change by 0%, while EPS estimates moved Revise Upward by 0.33% . This trend suggests that price dips could present buying opportunities for investors.
What should investors expect from ACB's next earnings report?
Based on historical trends, ACB's stock price typically moves by +1.38% in the 10 days before its earnings and -3.74% in the 10 days after. For the upcoming 2026/Q3 earnings, analysts expect an EPS of -0.10 and revenue of 92.43M.
What is the sentiment in Aurora Cannabis Inc (ACB) Q2 2026 Earnings Call Summary?
The earnings call presents a mixed bag: strong growth in medical cannabis and plant propagation segments, but declining consumer cannabis revenue and increased SG&A expenses. The Q&A highlights structural advantages in international markets but reveals uncertainties in regulatory environments and cash flow challenges. Despite positive adjusted net income and margin improvements, negative free cash flow and unclear guidance on regulatory impacts temper optimism. Without market cap details, a neutral stance is prudent, reflecting balanced positive and negative factors.

